Bonviva Effective as a Once-Monthly Oral Formulation for Osteoporosis

2006/07/31 16:57

Pressemeldung der Firma:

RxChemist.co.uk

RxChemist.co.uk continues its lead in the provision of the newest prescription medication to its customers.

Ibandronate (ibandronic acid) once monthly (Bonviva 150mg) received a positive opinion on granting a marketing authorisation from the European Medicines Evaluation agency in June 2005.

The licensed indication for ibandronate once monthly will be the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.

With once-monthly Bonviva, a potent and highly effective bisphosphonate,1 patients will only have to

Bonviva Effective as a Once-Monthly Oral Formulation for Osteoporosis

Health through Care

take 12 tablets a year versus 52 required with current weekly bisphosphonate treatments.

Pricing and ordering information is available form rxchemist.co.uk.